News summary
Newsletter text
[Sima Eyepennpursuit38000priceHong Kong, a wholly-owned subsidiary, sells its stake in BelkinVision Ltd.] Hima Ophthalmology announced that its wholly-owned subsidiary, Hong Kong, has sold its stake in BelkinVision Ltd. to Alcon Pharmaceuticals Ltd. with a book value of HK$23.3 million. The transaction includes a fixed cash consideration of approximately US$6.4 million and a contingent consideration of no more than US$17 million, depending on whether milestones associated with annual sales targets are met. Prior to the sale, Hong Kong Eye Healthcare held approximately 10% of the sold companypennpursuit38000price.7% equity or 8.6% equity on a fully diluted basis. The company's main business is to develop and commercialize Eagle laser equipment, which is designed to provide front-line glaucoma care. It is worth noting that this product received the CE mark from medical device manufacturers MDR under the new European directive in May 2022 and was approved by the U.S. Food and Drug Administration in December 2023. Sima Ophthalmology expects to achieve a pre-tax gain of approximately HK$26 million from a fixed cash consideration of approximately US$6.4 million through this transaction.